Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cubist Pharmaceuticals has signed an exclusive agreement with AstraZeneca to promote and provide other support in the US for Merrem IV, an established broad spectrum IV antibiotic.
Subscribe to our email newsletter
Cubist will promote and support Merrem IV using its existing US acute care sales and medical affairs organizations. AstraZeneca will continue to provide marketing and commercial support for Merrem IV.
The agreement, effective July 1, 2008, establishes a baseline of $20 million annual revenue to Cubist that will be adjusted based on actual Merrem IV sales. Other terms of the agreement, including the performance incentives, are confidential.
Robert Perez, Cubist executive vice president and COO, said: “As a broad spectrum antibiotic, Merrem IV is an excellent fit with our Gram positive therapy, Cubicin, which has experienced the most successful IV antibiotic launch in US history in dollar terms.”